Biogen delays 'complex and unpredecented' Alzheimer’s drug application

Biogen previously said it expected to ask the FDA to approve its Alzheimer's drug aducanumab in “early 2020”.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.